CD274 and neoplasm: Immune checkpoint inhibitors (ICIs), such as CTLA4 and PD1/PDL1 blockade, that reactivate tumor‐associated effector T cells have demonstrated dramatic clinical efficacy and provide long‐term survival in a substantial fraction of patients (Hodi et al., 2010; Weber et al., 2015, 2017; Wolchok et al., 2017).